Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
A phase 1/2 trial of FAP-2286 in prostate cancer, run by Blue Earth Therapeutics Ltd, now recruiting.
Overview
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection is a phase 1/2 interventional study registered as NCT05413850 by Blue Earth Therapeutics Ltd, with 82 participants planned, started 2022-07-20 and due to reach its primary completion in 2026-08-27. Interventions recorded: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only). Conditions listed: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.
- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.
- RoadmapRadiopharmaceutical roadmap: iodine → lutetium → actinium
Shares FAP-2286 (177Lu / 68Ga), Prostate cancer.